Treatment of Metastatic Colon Cancer with BRAF V600E Mutation (pMMR/MSS, KRAS/NRAS Wild-Type) After Progression Through Available Regimens
This protocol addresses proficient mismatch repair (pMMR) / microsatellite stable (MSS) metastatic colon adenocarcinoma in patients whose tumour carries a BRAF V600E mutation while remaining KRAS and NRAS wild-type. This molecular constellation defines a distinct subpopulation with specific treatment considerations, particularly when disease has progressed through prior lines of therapy.
Molecular Profile
- Mismatch repair status: proficient (pMMR) / microsatellite stable (MSS)
- KRAS: wild-type
- NRAS: wild-type
- BRAF: V600E mutation present
Treatment Approach — Overview
For this molecular subtype when disease has progressed through all available regimens, the protocol specifies salvage-line systemic options that include both a preferred combination approach and monotherapy alternatives. The complete regimen selection, preferred agent, and sequencing criteria are detailed in the full protocol.
References
- pMMR/MSS
- KRAS WT/NRAS WT/BRAF V600E Mutation
- Trifluridine and Tipiracil ± Bevacizumab (Bevacizumab combo preferred)
- Fruquintinib
- Regorafenib
View source ↗